FDA does about-face on review of potential ALS treatment from Amylyx

The Food and Drug Administration has reversed an internal decision and will now review an experimental treatment for amyotrophic lateral sclerosis — a victory for ALS patients and advocates who have been pressuring regulators to act with more urgency against the fatal, neuro-degenerative disease.

Amylyx Pharmaceuticals, a Cambridge, Mass.-based drug maker, said Wednesday that it will submit an application for its ALS treatment, called AMX0035, “in the coming months.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Most Related Links :
newsbinding Governmental News Finance News

Source link

Back to top button